The status of liver transplantation. by Starzl, TE
TECHNOLOGY IN SURGERY ~~~~~~~~~~~~~~~~~ 
The status of liver transplantation 
by Thomas E. Starzl, MD, F ACS, Pittsburgh 
Reprinted from the Bulletin of the American College of Surgeons, May 1985 
TECHNOLOGY IN SURGERY 
The status of liver transplantation 
by Thomas E. Starzl, MD, F ACS, Pittsburgh 
The number of medical centers that perform liver 
transplantations in the United States is small but 
growing. About a dozen centers have had experience 
in performing half a dozen or more liver transplants. 
Other centers with lesser experience are now be-
ginning to spring up-in Phoenix, Jackson, Birming-
ham, Madison, Milwaukee, Boston, and Phila-
delphia. Some of these have attained outstanding 
results. 
In Europe there are now almost a dozen medical 
centers as well that have experience with a half a 
dozen or more cases, and some other centers are 
beginning to develop-a second center in London, 
one in Oslo, in Helsinki, Innsbruck, Milan, Nice, and 
Rome. This extraordinary growth in the number of 
centers affords the possibility of establishing a 
European network similar to what we hope to de-
velop in the United States. 
As of September 1984, a total of 568 orthotopic 
liver transplantations had been carried out in the 
United States over the past 20 years. Almost half 
of the recipients are still alive. In 1983 alone, 145 
liver transplants were performed, more than the 
number done the previous year. It is difficult to col-
lect accurate survival figures from the various centers 
because of the differences in data collection and, per-
haps more importantly, the differences in when these 
programs were begun. 
Until the advent of cyclosporine in 1980, sur-
vival prospects for liver transplant patients were 
poor. In my own experience at the University of 
Colorado with an initial series of some 120 patients. 
two-thirds of the patients had died by the end of the 
first year. In a later series, the one-year survival 
rose to 50 percent. but a third series of patients had 
a one-year survival rate of about 40 percent. The 
limiting factor in these operations was that there was 
no margin of safety between toxicity and therapeutic 
levels of drugs in either the double-drug (azathi-
oprine-prednisone) or triple-drug programs, the 
latter including antilymphocyte globulin. 
The only really encouraging thing about that early 
dreary experience was that patients who lived for 
one or, especially, two years had an extraordinary 
chance of living for a long time afterward. About 
one in five of the patients who received liver trans-
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plants at the University of Colorado between 1963 
and 1980 are still alive. 
Cyc1osporine has had a tremendous influence on 
survival. Better than two-thirds of patients treated 
with cyc1osporine-steriod therapy since early 1980 
survived for one year. Among patients I treated at the 
University of Colorado in 1980, survival was about 
80 percent. In 1981, my first year at Pittsburgh, pa-
tient survival was almost as good. Then in 1982, 
one-year survival went down to 50 percent. This was 
the first year of truly mass production of liver trans-
plantation operations. In one year, we treated 62 
new patients plus some 20 who underwent re-
transplan tation. 
It also was a year of intensive training of multiple 
teams to perform donor hepatectomies, and a time 
when several younger faculty members were gain-
ing experience with the recipient operation. The pay-
off came in subsequent years in which the survival 
went up to its present rate of over 80 percent. 
Perioperative mortality 
We have found that perioperative mortality can be 
reduced in a number of ways: 
• By using venovenous bypasses, almost always 
done in adults, but also for selected pediatric 
patients. 
• With double-route therapy, i.e., administering 
cyclosporine intravenously until the degree of gastro-
intestinal absorption of this important drug can be 
accurately assessed. 
• And finally, with a policy of aggressive retrans-
plantation. 
Retransplantation in the past, under conventional 
therapy, was extremely unsuccessful. Only about one 
in six or one in seven patients undergoing retrans-
plantation lived as long as six months and most of 
those died shortly after one year. Under cyclosporine 
steroid therapy, particularly because heavy steroids 
are not necessary, the number \vho survive more than 
six months is almost half. And those results are 
slowly edging up toward the success rate achieved 
after primary transplantation. Incidentally, there 
have been two or three patients who have received 
three grafts and arc still alive. 
The effectiveness of oral administration of cyclo-
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sporine can be determined, as the pioneering work 
done in London, Ontario, and in Houston by Kahan 
has shown, by measuring cyclosporine levels in the 
blood. Double-route therapy is rather complex, but 
competent internists are accustomed to the technique 
in assessing therapy with other drugs. If cyclosporine 
levels are not adequate, alternative therapy can be 
used. I believe that the discriminating use of mono-
clonal antibody therapy is going to provide a tre-
mendous advantage to recipients of extra-renal 
organs, such as the liver and the heart. Weare, 
among others, working on this possibility at the 
present time. 
Venovenous bypasses were used in the labora-
tory development of liver transplantation a quarter 
of a century ago, but have not been used clinically 
for almost 20 years because they were thought to be 
unnecessary. The bypasses return blood to the upper 
half of the body and thus to the heart during the 
obligatory occlusion of the vena cava and portal 
vein while the new liver is being sewn in. And 
although most patients can survive this insult, 
it is a major insult, leading to third-party fluid 
sequestration, swelling of the gut, a high incidence 
of renal failure and the necessity for preloading, and 
then subsequent pulmonary edema during the post-
operative period. The physiologic advantages of the 
bypass were reported by Shaw at the American Sur-
gical Association meeting last spring and published 
in the Annals of Surgery (200:524, 1984). Bypass 
systems are advantageous to the patient and should 
not be avoided in any adult or even large pediatric 
patient. 
Technical problems 
A couple of technical problems had to be resolved 
before the field of transplantation could move for-
ward. Biliary tract reconstruction has been the most 
perplexing problem until relatively recently. The 
present methods of biliary tract reconstruction are 
duct-to-duct anastomosis over a stent, usually a 
T-tube stent, or if that fails, a duct-to-Roux limb 
anastomosis over a stent. These are almost, but not 
quite, foolproof methods of reconstruction. And in 
England, CaIne still uses a procedure originally in-
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troduced by Waddell of Colorado: the gallbladder 
itself is used as a conduit between the common duct, 
which is anastomosed to it, and the recipient com-
mon duct or intestine. CaIne is pleased with this 
method of reconstruction, but it is more complex 
than conventional methods and I think that the use 
of this operation will probably decline. 
With the number of cases increasing along with 
the number of new centers entering the field of liver 
transplantation, altruistic cooperation among cities 
and groups has led to a standardization of procure-
ment procedures designed to remove not only the 
liver but also the kidneys and, in many instances, the 
heart from the same donor. These multiple organ 
procurement procedures have in common mobiliza-
tion of the central abdominal vessels (the aorta) and 
control of the vena cava, which allows for controlled 
infusion of cold fluids into specific organs. 
Vascular grafts should be removcd in every organ 
procurement procedure because there are so many 
anomalies among liver transplant recipients that 
in about a third or a fourth of the cases, large iliac 
grafts must be used to plug into the recipient aorta 
and act as conduits in order to revascularize the 
donor liver. It would be a great tragedy to find such 
a situation in the recipient and realize that these 
grafts were in the morgue with thc donor. 
An alternative method of organ removal that 
can be used for non-heart-beating donors is to put 
cold fluids up into the aorta. These fluids immedi-
ately pass into the splanchnic circulation and almost 
immediately infuse the liver. This method protects 
the kidneys as well as the liver and it can be per-
formed quickly. 
With this method, body temperature drops into 
thc cryoprotective range within one minute and then 
drifts down into the deeply cryoprotective range over 
a period of five minutes or so. The explanation for 
the quick and effective liver preservation is that the 
hematocrit level of the portal vein drops so quickly 
that within two minutes preservation fluid, after pass-
ing through the splanchnic capillary bed, perfuses the 
liver. The temperature of the kidney also falls quickly. 
This method could be used in those countries in 
Europe, principally Scandinavian countries, in 
which brain death has not yet been legally defined. 
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Indications for transplantation 
The indications for liver transplantation-what Dr. 
John Najarian has colorfully termed the textbook 
of liver disease-represent a very long list. How-
ever, the principal indication is liver failure. With-
in the past year, three other diseases-Crigler-
Najjar's syndrome (a glucuronyl transferase de-
ficiency), congenital oxalosis, and familial hyper-
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cholesterolemia-have all been treated with liver 
transplantation despite the fact that the removed 
livers were seemingly normal. 
The future of liver transplantation is encouraging 
because so many bright young surgeons can now 
perform the procedure. As the field grows, so will 
the expertise of its practitioners and the benefits to 
the patient. 
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